Meeting
2021 ASCO Annual Meeting
Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.
Authors
Shugeng Gao
Thoracic Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Shugeng Gao , Ning Li , Shunyu Gao , Qi Xue , Shuhang Wang , Fang Lv , Liang Zhao , Fan Zhang , Ziran Zhao , Kai Su , Fengwei Tan , Yun Ling , Zhijie Wang , Wei Tang , Jianming Ying , Ning Wu , Jie Wang , Jie He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
ChiCTR-OIC-17013726
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8522)
DOI
10.1200/JCO.2021.39.15_suppl.8522
Abstract #
8522
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
First Author: Dwight Hall Owen
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2022 ASCO Annual Meeting
PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
First Author: Stephanie Saw
Poster
2022 ASCO Annual Meeting
Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.
First Author: Richard Cathomas